Literature DB >> 14744874

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

Tomohiko Usui1, Susumu Ishida, Kenji Yamashiro, Yuichi Kaji, Vasiliki Poulaki, Johnny Moore, Tara Moore, Shiro Amano, Yoshitaka Horikawa, Darlene Dartt, Matthew Golding, David T Shima, Anthony P Adamis.   

Abstract

PURPOSE: Vascular endothelial growth factor (VEGF) induces angiogenesis and vascular permeability and is thought to be operative in several ocular vascular diseases. The VEGF isoforms are highly conserved among species; however, little is known about their differential biological functions in adult tissue. In the current study, the inflammatory potential of two prevalent VEGF isoform splice variants, VEGF(120(121)) and VEGF(164(165)), was studied in the transparent and avascular adult mouse cornea.
METHODS: Controlled-release pellets containing equimolar amounts of VEGF(120) and VEGF(164) were implanted in corneas. The mechanisms underlying this differential response of VEGF isoforms were explored. The response of VEGF in cultured endothelial cells was determined by Western blot analysis. The response of VEGF isoforms in leukocytes was also investigated.
RESULTS: VEGF(164) was found to be significantly more potent at inducing inflammation. In vivo blockade of VEGF receptor (VEGFR)-1 significantly suppressed VEGF(164)-induced corneal inflammation. In vitro, VEGF(165) more potently stimulated intracellular adhesion molecule (ICAM)-1 expression on endothelial cells, an effect that was mediated by VEGFR2. VEGF(164) was also more potent at inducing the chemotaxis of monocytes, an effect that was mediated by VEGFR1. In an immortalized human leukocyte cell line, VEGF(165) was found to induce tyrosine phosphorylation of VEGFR1 more efficiently.
CONCLUSIONS: Taken together, these data identify VEGF(164(165)) as a proinflammatory isoform and identify multiple mechanisms underlying its proinflammatory biology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744874     DOI: 10.1167/iovs.03-0106

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  50 in total

Review 1.  Vascular endothelial growth factor biology: clinical implications for ocular treatments.

Authors:  R B Bhisitkul
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

Review 2.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

3.  Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction.

Authors:  Walter Cromer; Merilyn H Jennings; Yoshinubo Odaka; J Michael Mathis; J Steven Alexander
Journal:  Microcirculation       Date:  2010-10       Impact factor: 2.628

4.  VEGF₁₆₄ isoform specific regulation of T-cell-dependent experimental colitis in mice.

Authors:  John H Chidlow; John D Glawe; Christopher B Pattillo; Sibile Pardue; Songlin Zhang; Christopher G Kevil
Journal:  Inflamm Bowel Dis       Date:  2010-11-09       Impact factor: 5.325

5.  Implantation of VEGF-functionalized cell-free vascular grafts: regenerative and immunological response.

Authors:  Randall J Smith; Tai Yi; Bita Nasiri; Christopher K Breuer; Stelios T Andreadis
Journal:  FASEB J       Date:  2019-01-10       Impact factor: 5.191

6.  Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.

Authors:  M Elizabeth Hartnett; David J Martiniuk; Yuta Saito; Pete Geisen; Lynda J Peterson; Janet R McColm
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

7.  Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1.

Authors:  Francesca Seta; Kiran Patil; Lars Bellner; Alexandre Mezentsev; Rowena Kemp; Michael W Dunn; Michal Laniado Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-05-21       Impact factor: 3.072

8.  Age-related macular degeneration: current treatment and future options.

Authors:  Tanya Moutray; Usha Chakravarthy
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

9.  Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration.

Authors:  Sobha Sivaprasad
Journal:  Clin Ophthalmol       Date:  2008-06

10.  Photoreceptor degeneration and retinal inflammation induced by very low-density lipoprotein receptor deficiency.

Authors:  Ying Chen; Yang Hu; Gennadiy Moiseyev; Kevin K Zhou; Danyang Chen; Jian-xing Ma
Journal:  Microvasc Res       Date:  2009-03-10       Impact factor: 3.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.